Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2021
2022
2023
2024
2025
Oragenics Inc (OGEN)
Price—Loading quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2012
2013
2014
2015
2016
2018
2019
2021
2022
2023
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $37,653 | $131,521 | $86,987 | — | — | — | $0 | $0 | $0 | $939,926 | $1.0M | $1.3M | $1.4M | $1.3M |
| Gross profit | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $570,329 | $688,879 | $453,303 | $730,820 | $397,117 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | 60.68% | 66.74% | 34.04% | 50.60% | 30.34% |
| Research & development | $2.4M | $4.1M | $15.5M | $10.1M | $10.6M | $22.1M | $12.1M | $6.0M | $3.5M | $4.8M | $8.7M | $3.1M | $9.4M | $7.9M | $2.4M | $2.0M |
| Operating expenses | $9.4M | $10.6M | $20.9M | $14.6M | $15.9M | $26.6M | $15.9M | $10.0M | $6.7M | $8.5M | $11.8M | $6.4M | $16.9M | $12.9M | $8.1M | $8.3M |
| Operating income | −$9.4M | −$10.6M | −$20.9M | −$14.4M | −$15.8M | −$26.6M | −$15.9M | −$10.0M | −$6.7M | −$8.5M | −$11.8M | −$5.8M | −$16.2M | −$12.4M | −$7.3M | −$7.9M |
| Operating margin | — | — | −55,519.89% | −10,964.61% | −18,130.32% | — | — | — | — | — | — | −618.82% | −1,570.40% | −933.52% | −508.59% | −603.76% |
| EBITDA | −$9.2M | −$10.5M | −$20.9M | −$14.4M | −$15.7M | −$26.6M | −$15.8M | −$10.0M | −$6.7M | −$8.5M | −$11.7M | −$5.8M | −$16.1M | −$12.4M | −$7.3M | −$7.9M |
| EBITDA margin | — | — | −55,447.14% | −10,930.65% | −18,082.91% | — | — | — | — | — | — | −615.88% | −1,562.99% | −927.88% | −503.09% | −600.49% |
| Net income | −$9.8M | −$10.6M | −$20.7M | −$14.3M | −$15.7M | −$26.4M | −$15.6M | −$9.9M | −$6.7M | −$7.0M | −$11.7M | −$5.8M | −$16.1M | −$13.1M | −$7.7M | −$7.8M |
| Net profit margin | — | — | −54,858.14% | −10,863.96% | −18,062.03% | — | — | — | — | — | — | −615.95% | −1,556.70% | −982.94% | −531.61% | −596.31% |
| Basic EPSper basic share | -$4.56 | -$47.88 | -$275.40 | -$213.30 | -$242.70 | -$817.80 | -$643.80 | -$1,513.80 | -$2,383.80 | -$2,731.80 | -$5,568.00 | -$2,784.00 | -$9,744.00 | -$12,876.00 | -$23,316.00 | -$24,708.00 |
| Diluted EPSper diluted share | -$4.56 | -$47.88 | -$275.40 | -$213.30 | -$243.60 | -$817.80 | -$643.80 | -$1,513.80 | -$2,383.80 | -$2,731.80 | -$5,568.00 | -$2,784.00 | -$9,744.00 | -$12,876.00 | -$23,316.00 | -$24,708.00 |
Owners
Reported shareholders
≈0.57%of listed shares
DUNTON ALAN W25.62K shares · Dec 6, 2024
View holders
| Holder | % owned |
|---|---|
KOSKI ROBERT C | —51.31K shares |
DUNTON ALAN W | ≈0.57%25.62K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.52%23.69K shares |
25 LLC | 0.51%23.16K shares |
JANE STREET GROUP, LLC | 0.28%12.77K shares |
Tower Research Capital LLC (TRC) | 0.10%4.55K shares |
St. Johns Investment Management Company, LLC | 0.04%1.92K shares |
Telling Fred | —948 shares |
BlackRock, Inc. | 0.02%703 shares |
UBS Group AG | 0.01%642 shares |
WELLS FARGO & COMPANY/MN | <0.01%34 shares |
HARBOUR INVESTMENTS, INC. | <0.01%34 shares |
SBI Securities Co., Ltd. | <0.01%23 shares |
ADKINS SEALE CAPITAL MANAGEMENT LLC | <0.01%3 shares |
ROYAL BANK OF CANADA | <0.01%2 shares |
Johnson Financial Group, Inc. | <0.01%1 shares |
Bogart Wealth, LLC | <0.01%1 shares |
Strategic Wealth Partners, Ltd. | <0.01%1 shares |
Farther Finance Advisors, LLC | <0.01%1 shares |
Keating Financial Advisory Services, Inc. | <0.01%1 shares |
Percentages use 4.51M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 12, 2025Form 4/A | Telling FredDirector | SellCommon Stock | 210 | $0.94 | $197.40 | 948 |
| Dec 12, 2025Form 4 | Telling FredDirector | SellCommon Stock | 210 | $0.94 | $197.40 | 34.5K |
| Jun 18, 2025Form 4 | Odyssey Health, Inc.TenPercentOwner | SellCommon Stock - OGEN | 5.0K | $4.26 | $21.5K | 0 |
| Jun 17, 2025Form 4 | Odyssey Health, Inc.TenPercentOwner | SellCommon Stock - OGEN | 2.0K | $4.46 | $8.9K | 5.0K |
| Jun 16, 2025Form 4 | Odyssey Health, Inc.TenPercentOwner | SellCommon Stock - OGEN | 5.0K | $4.45 | $22.3K | 7.0K |